Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CCR4 | P51679 | 2/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627063 | 0.78 | CCR4 (0.48) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL13209712 | 0.78 | HTR2A (0.45) | GABRA1GABRB2ALDH1A1TSHRATM | |
| SCHEMBL26596970 | 0.77 | CYP3A4 (0.39) | ALDH1A1TSHRTDP1PGRAR | |
| SCHEMBL13209355 | 0.77 | NOTUM (0.50) | HSD11B1PGRNR3C2DRD2HTR6 | |
| SCHEMBL19000959 | 0.77 | CA2 (0.35) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL14584041 | 0.74 | GPR3 (0.37) | CA2ALDH1A1TSHRTDP1KIF11 | |
| SCHEMBL15079231 | 0.74 | CA2 (0.36) | CA2GABRA1GABRB2ALDH1A1TSHR | |
| SCHEMBL18125586 | 0.74 | — | — | |
| SCHEMBL13209348 | 0.74 | HTR2C (0.49) | CA2ALDH1A1DRD2HTR6 | |
| SCHEMBL1312418 | 0.73 | HTR6 (0.38) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2013-06-27 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | CA2 3936/4885GABRA1 2231/4885GABRB2 2437/4885 |
| US-20130165475-A1 | DEUTERIUM-ENRICHED HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK2, CDK1, CDK3 | CA2 4378/4885GABRA1 4707/4885GABRB2 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.